Glycyl-L-Tyrosine Market

A media scientist who orders glycyl-L-tyrosine in a 25-gram catalogue bottle from Sigma-Aldrich pays USD 839, or USD 33,560 per kilogram, while a biomanufacturer buying crystalline dihydrate by the drum pays about USD 1,480, by our estimate. That nearly 23-fold gap frames every sourcing call in this dipeptide. The glycyl-L-tyrosine market covers the dipeptide of glycine and L-tyrosine sold as a cell culture feed ingredient, a parenteral nutrition active pharmaceutical ingredient (API), a research reagent and a cosmetic or nutrition ingredient. Our model counts 12,640 kilograms shipped in 2025 at a blended USD 1,669.3 per kilogram, which equals USD 21.1 million, and takes revenue to USD 44.0 million by 2035, a 7.64% revenue CAGR. Upstream supply changed hands on 1 July 2025, when Kirin Holdings completed the transfer of Kyowa Hakko Bio’s amino acid business to a subsidiary of Meihua Holdings Group. The study is part of our pharmaceuticals research, and each figure follows the Douglas Insights research methodology.

Why are fed-batch feed designers switching to glycyl-L-tyrosine?

Glycyl-L-tyrosine volume rises 6.15% a year because biologics plants want concentrated, neutral-pH feeds, and free L-tyrosine dissolves at under 0.5 g per litre. Four forces add up to that volume leg: fed-batch intensification, perfusion adoption, the switch to chemically defined media and Chinese parenteral nutrition use.

Fed-batch intensification contributes 2.38 points. Evonik states that free L-tyrosine dissolves at less than 0.5 g per litre at neutral pH, and that its cQrex GY glycyl-L-tyrosine dihydrate raises solubility by up to 50 times. A feed that once needed a separate alkaline tyrosine stream can now carry about 25 g per litre of the dipeptide in a single neutral bottle. Douglas Insights counts 9,224 kilograms of glycyl-L-tyrosine going into cell culture media and feeds in 2025, 73.0% of all kilograms shipped, and most of it into high-titre monoclonal antibody processes run by Chinese hamster ovary (CHO) cell lines.

Perfusion adds 1.64 points. Continuous perfusion bioreactors exchange one or more vessel volumes of medium a day, so a 2,000-litre perfusion run consumes several times the medium of a fed-batch run of the same size. Concentrated basal media for perfusion need every amino acid at high strength, and tyrosine is the classic solubility limit. Our model assumes the perfusion share of glycyl-L-tyrosine kilograms rises from about 19% in 2025 to about 31% by 2035, which on its own lifts annual volume growth by 1.64 points.

Chemically defined, animal-origin-free media contribute 1.21 points. Evonik describes cQrex GY as free of animal origin and chemically defined, supplied as a pure crystalline substance for full replacement of L-tyrosine. Sponsors favour defined components over non-defined complex mixtures, a preference Evonik builds its cQrex range around. Douglas Insights expects at least 4 in 5 new chemically defined feed platforms launched through 2030 to carry a soluble tyrosine source, and glycyl-L-tyrosine is the longest established of those peptides in our supplier review.

Chinese parenteral nutrition adds the last 0.92 points. IQVIA sales data cited at Jinyao Pharmaceuticals’ glycyl-tyrosine API approval put annual global API consumption at 260.4 kg, with China taking 197.9 kg, or 76.0%. Our model grows that API stream to about 291 kilograms in 2025, used in compound amino acid (15) dipeptide (2) injections for patients who cannot be fed orally or enterally. The four drivers sum to 2.38 + 1.64 + 1.21 + 0.92 = 6.15 points, the full volume leg.

Which bottlenecks keep glycyl-L-tyrosine out of more infusion bags and feed bottles?

Three bottlenecks remove 1.32 points from glycyl-L-tyrosine volume growth: rival tyrosine peptides, the persistence of pH-extreme L-tyrosine side feeds and the shrinking number of dipeptide infusions in Europe. Without them, unit growth would run at 7.47% a year instead of 6.15%, worth about USD 5.8 million of extra revenue in 2035.

Rival peptides take 0.57 points. Evonik itself sells cQrex AY, L-alanyl-L-tyrosine trihydrate, alongside cQrex GY, so a media formulator can pick either dipeptide from one supplier. Douglas Insights estimates that 14% of new peptide-based tyrosine formulations in 2025 chose a non-glycyl option, and each 5-point gain for alanyl-tyrosine costs glycyl-L-tyrosine about 0.2 points of annual growth.

Legacy side feeds take 0.44 points. Many commercial antibody processes were validated a decade ago with a separate high-pH L-tyrosine and L-cystine feed. Changing a validated feed means comparability studies and a regulatory variation, so owners keep the old recipe until a process change is due. We assume about 58% of commercial-stage glycyl-L-tyrosine candidate processes keep the pH-extreme feed through 2030. Free L-tyrosine also costs a small fraction of the dipeptide per kilogram, which keeps cost-driven teams on the old route.

European infusion withdrawals take 0.31 points. In Ireland the Glamin solution for infusion licence held by Fresenius Kabi, first granted on 9 May 1996, was withdrawn on 30 September 2011. Glamin combined glycyl-glutamine and glycyl-tyrosine dihydrate with 15 free amino acids. Fewer licensed multi-chamber bags with dipeptides in Europe leave China as the main parenteral outlet for glycyl-L-tyrosine API.

Which application segment of glycyl-L-tyrosine makes the money, cell culture feeds or parenteral nutrition?

Cell culture media and feeds lead glycyl-L-tyrosine revenue with 64.7%, or USD 13.65 million in 2025, because biologics plants buy the dipeptide by the drum. The same segment grows fastest at 8.71% a year, as perfusion and concentrated feeds raise grams of tyrosine per litre of product.

Cell culture media and feeds earn USD 13.65 million and reach USD 31.47 million by 2035; the segment holds its share because one 12,000-litre antibody campaign can absorb several kilograms of glycyl-L-tyrosine. Research and peptide reagents are worth USD 4.98 million despite only about 508 kilograms, since catalogue prices run from USD 7,601 to USD 33,560 per kilogram; growth of 5.38% follows academic and process-development budgets. Cosmetics and nutrition ingredients add USD 1.43 million from about 2,617 kilograms at a low USD 548 per kilogram, with 5.92% growth from tyrosine-based skin and supplement formulations. Parenteral nutrition API is the smallest line at USD 1.03 million and the slowest at 4.46%, because hospital use of dipeptide infusions is concentrated in China. Media buyers who also track single-use bags will find the consumables side in our Biopharmaceutical Single-Use Bioprocessing Market study.

By grade, the coverage splits into Cell culture grade, Pharmaceutical GMP grade, Research grade and Cosmetic grade. By form, it splits into Crystalline dihydrate and Anhydrous powder. By end user, the buyers are Biopharmaceutical manufacturers, Media formulators, Parenteral nutrition makers and Academic and research laboratories.

Where do biomanufacturing hubs pull glycyl-L-tyrosine volume, region by region?

North America leads glycyl-L-tyrosine revenue with USD 7.87 million in 2025, 37.3% of the total, on the largest installed base of commercial antibody bioreactors. Asia Pacific grows fastest at 9.68% a year, reaching USD 14.03 million by 2035, as Chinese and Korean contract plants scale fed-batch and perfusion lines.

North America climbs to USD 15.51 million by 2035 at 7.02% a year, carried by US antibody plants and the media houses that supply them. Europe holds USD 6.50 million in 2025 and reaches USD 12.16 million at 6.47%, the slowest rate, as validated legacy processes hold on to L-tyrosine side feeds; Evonik’s Ham plant in northern France still exports more than 93% of its output. Asia Pacific starts at USD 5.57 million and nearly matches North America by 2035 because China already uses 76.0% of glycyl-tyrosine API and its biologics contract capacity keeps expanding. Latin America earns USD 0.70 million in 2025 and USD 1.35 million in 2035 at 6.83%, mostly research reagents and imported media. The wildcard is the Middle East and Africa at USD 0.46 million growing 7.52% a year to USD 0.95 million; a single regional biosimilar plant using concentrated feeds would lift that rate by more than 2 points in our model.

Which suppliers control crystalline glycyl-L-tyrosine dihydrate output?

Evonik holds 41.6% of glycyl-L-tyrosine revenue in 2025 by Douglas Insights estimate, built on cell culture grade cQrex GY made at Ham, France. With Merck KGaA’s Sigma-Aldrich and Thermo Fisher Scientific, the top three hold 58.9%, a figure anchored on segment values rather than disclosed product revenue.

Evonik’s lead rests on scale and registration depth: its Ham site employs about 230 people, exports more than 93% of output and has products registered in more than 60 countries, and it became carbon neutral in May 2023. Merck KGaA, through Sigma-Aldrich, wins on catalogue reach; its 25-gram bottle at USD 839 sets the top of the research price band. Thermo Fisher Scientific sells a 100-gram pack at USD 1,232 under Thermo Scientific Chemicals. Bachem lists H-Gly-Tyr-OH at USD 190.03 for 25 grams, the lowest catalogue price we read. TCI supplies the hydrate in 1-gram and 5-gram packs across Asia Pacific and Europe. Jinyao Pharmaceuticals holds National Medical Products Administration (NMPA) approval for glycyl-tyrosine as an API, giving Chinese infusion makers a domestic source. Fresenius Kabi owns the Glamin brand, the best documented glycyl-tyrosine infusion outside China. Meihua Holdings Group, which Kirin describes as a leading Chinese bio-manufacturing company, has owned the former Kyowa Hakko Bio amino acid business since 1 July 2025 and sits one step upstream of dipeptide makers.

What does glycyl-L-tyrosine cost per kilogram, from catalogue bottle to GMP drum?

Realised glycyl-L-tyrosine prices run from about USD 548 per kilogram for cosmetic grade to USD 33,560 for a 25-gram research bottle, with a 2025 blended average of USD 1,669.3. Pack size, grade and documentation explain nearly all of the spread, and the blend rises 1.40% a year.

Douglas Insights puts cell culture grade glycyl-L-tyrosine dihydrate at about USD 1,480 per kilogram in drum quantities, with animal-origin-free documentation and supply security included. Pharmaceutical GMP grade API for infusions sells near USD 3,550 per kilogram, since each lot carries a drug master file and full impurity testing. Research catalogue prices are far higher: USD 7,601 per kilogram at Bachem, USD 12,320 at Thermo Fisher Scientific and USD 33,560 at Sigma-Aldrich. Cosmetic and nutrition grades clear at about USD 548. The 1.40% price leg reflects mix shift toward GMP and cell culture grades rather than list price increases. By 2035, our blended price reaches USD 1,918 per kilogram.

Buyers who need sterile finished infusions rather than API should read our Sterile Injectable Contract Manufacturing Market study, which covers the fill step where dipeptide solutions are made.

Does neutral-pH solubility make glycyl-L-tyrosine the default tyrosine source in perfusion media?

Not yet: perfusion processes take about 19% of glycyl-L-tyrosine kilograms in 2025 in our model, although the dipeptide dissolves at roughly 25 g per litre against under 0.5 g for free L-tyrosine. Validation inertia and rival peptides keep glycyl-L-tyrosine from becoming the perfusion default before about 2031.

The chemistry favours the glycyl dipeptide. Evonik states that cQrex GY is efficiently taken up and metabolised by the cell, so it can fully replace L-tyrosine in a feed. A neutral concentrated feed avoids precipitation and pH spikes in the bioreactor, which matters most in perfusion where medium is pumped continuously. Douglas Insights expects the perfusion share of glycyl-L-tyrosine kilograms to reach about 31% by 2035, adding roughly 4,700 kilograms of annual use over the decade.

Is the dipeptide infusion bag still an outlet for glycyl-L-tyrosine API?

Yes, but a small one: parenteral nutrition takes about 291 kilograms of glycyl-L-tyrosine API in 2025, worth USD 1.03 million, and grows 4.46% a year. Most of that API goes into Chinese compound amino acid dipeptide injections for patients who cannot receive enteral nutrition.

Formulation data show how little API each bag needs. The South African Glamin professional information, revised on 11 November 2025, lists 3.46 g of glycyl-tyrosine dihydrate per litre, supplying 2.28 g of tyrosine, inside 134 g of total amino acids. That puts glycyl-L-tyrosine at 2.58% of amino acid mass. A Glamin-strength 500 mL bag holds 1.73 g, so our 291 kilograms equal about 168,300 bags a year. The product was first authorised in South Africa on 12 March 1999.

Which pharmacopoeial and drug-master rules govern glycyl-L-tyrosine API and media grades?

Two rule sets apply to glycyl-L-tyrosine: drug registration for API used in infusions, and supplier quality standards for cell culture grades. In China, API makers need an NMPA approval linked to each finished injection, as Jinyao Pharmaceuticals obtained for glycyl-tyrosine; media grades follow customer audits instead.

For infusions, glycyl-L-tyrosine enters the finished product licence of each country, as Glamin’s Irish and South African records show; the HPRA classifies it under parenteral nutrition code B05BA. For cell culture, no monograph sets the grade, so biologics sponsors rely on supplier change-control agreements, animal-origin-free statements and elemental impurity data. Douglas Insights counts 3 documentation layers that separate the USD 1,480 cell culture grade from the USD 548 cosmetic grade: origin statements, impurity profiles and change notification.

What if perfusion adoption or alanyl-tyrosine substitution moves the 2035 glycyl-L-tyrosine forecast?

Our base case gives glycyl-L-tyrosine USD 44.0 million in 2035 from 6.15% volume and 1.40% price growth. A slower case gives USD 34.2 million and a faster case USD 57.1 million. Perfusion uptake, the alanyl-tyrosine share and Chinese API pricing after the Meihua takeover decide which path holds.

The slower case uses 4.10% volume and 0.80% price growth, a 4.93% revenue CAGR: alanyl-tyrosine wins most new perfusion media and Meihua’s ownership of the former Kyowa Hakko Bio amino acid business, effective 1 July 2025, pushes Chinese amino acid and dipeptide prices down. The faster case uses 8.30% volume and 2.00% price growth, a 10.47% revenue CAGR, with perfusion above 40% of new commercial capacity. One extra point of yearly unit growth adds USD 4.33 million to the 2035 base value. The only published glycyl-L-tyrosine growth rate we could read is 6.22% a year; our 7.64% sits 1.42 points above it because we model perfusion separately.

Douglas Exclusive: the Glycyl-L-Tyrosine Feed Substitution Matrix

The Glycyl-L-Tyrosine Feed Substitution Matrix is a Douglas Insights model, not an industry standard, built from 14 inputs. Those are 4 catalogue prices, 3 modelled bulk grade prices, 3 molecular weights, 2 solubility figures, 1 infusion formula and 1 consumption figure. The matrix converts every glycyl-L-tyrosine offer into dollars per kilogram of tyrosine actually delivered.

The matrix uses 181.19 for tyrosine, 238.24 for anhydrous glycyl-L-tyrosine and 274.27 for the dihydrate. Its first finding: at about 25 g per litre, a neutral glycyl-L-tyrosine feed carries 16.5 g of tyrosine per litre, 33 times the ceiling of free L-tyrosine. Its second finding: drum-grade dihydrate delivers tyrosine at USD 2,240 per kilogram, one-twentieth of the most expensive catalogue route. The Glamin formula checks the tyrosine fraction: 2.28 g out of 3.46 g is 65.9%, within 0.2 points of the theoretical 66.06%.

How does our methodology convert dipeptide kilograms into the glycyl-L-tyrosine revenue figure?

The model multiplies 12,640 kilograms of glycyl-L-tyrosine by USD 1,669.3 per kilogram to reach USD 21.1 million in 2025, then grows volume 6.15% and price 1.40% a year to USD 44.0 million in 2035. Four application segments and five regions reconcile to the global total.

Volume reaches 22,959 kilograms in 2035. Segment kilograms are 9,224 for cell culture, 508 for research, 2,617 for cosmetics and nutrition and 291 for parenteral API, which sum to 12,640. We counted 18 countries in the regional build and used 13 checked source facts. Cross-check one: the API line grows from IQVIA’s 260.4 kg base at 3.8% a year over 3 years to 291 kg. Cross-check two: the five regions sum to USD 21.1 million in 2025 and USD 44.0 million in 2035 within USD 0.05 million. Cross-check three: segment values for 2035 add to USD 44.03 million, 0.03% below the global figure. Adjacent fermentation inputs appear in our Precision Fermentation Ingredients Market study.

Sources

1. Kirin Holdings Completion of partial business transfer of Kyowa Hakko Bio (2025)
2. Evonik Enhancing the solubility of L-tyrosine in cell culture media applications (2023)
3. Evonik cQrex peptides and antioxidants for cell culture (2025)
4. Evonik Evonik Rexim site in Ham (2025)
5. South African Health Products Regulatory Authority Glamin professional information, revised 11 November 2025 (2025)
6. Health Products Regulatory Authority Glamin, solution for infusion (withdrawn) (2011)
7. Sigma-Aldrich (Merck KGaA) Gly-Tyr G3502 product page (2026)
8. Thermo Fisher Scientific N-Glycyl-L-tyrosine, 98% product page (2026)
9. Bachem H-Gly-Tyr-OH 4000165 catalogue listing (2026)
10. Tokyo Chemical Industry Glycyl-L-tyrosine Hydrate G0145 (2026)